Merck’s $3.5 billion deal reflects surging interest in fast-moving RNA IP landscape

Merck’s $3.5 billion deal reflects surging interest in fast-moving RNA IP landscape

Innovations in the space are attracting growing attention from investors and Big Pharma

Unlock unlimited access to all IAM content